Postpartum Depression Therapeutics Market Size in the 7MM was ~USD 260 Million in 2023, is expected to grow by 2034, and estimates DelveInsight

DelveInsight's "Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Explore the intricate details of the Postpartum Depression Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Postpartum Depression Market Forecast. Click here to stay ahead in healthcare innovation @ Postpartum Depression Market Size [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Postpartum Depression Market Research Report

* Among the seven major countries, the total Postpartum Depression diagnosed prevalence cases were ~1,310,000, in 2023.
* In EU4 and the UK, the total Postpartum Depression diagnosed prevalence cases were ~4,60,000 in 2023.
* In the seven major market, the United States accounted for the highest number of Postpartum Depression diagnosed cases (~720,000), followed by the UK, in 2023.
* In Japan, the total Postpartum Depression diagnosed prevalent cases were ~126,000 in 2023.
* The leading Postpartum Depression Companies such as Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace , and others.
* Promising Postpartum Depression Pipeline Therapies such as SAGE-217/BIIB-125, Ganaxolone, LPCN 1154, BRII-296 , and others.

Discover which therapies are expected to grab the Postpartum Depression Market Share @ Postpartum Depression Market Outlook [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Postpartum Depression Epidemiology Segmentation in the 7MM

- Total Postpartum Depression Diagnosed Prevalent Population of Maternal

Download the report to understand which factors are driving Postpartum Depression epidemiology trends @ Postpartum Depression Prevalence [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Postpartum Depression Marketed Therapies

* ZURZUVAE (zuranolone) : Sage Therapeutics/Biogen

Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a -aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing.

* ZULRESSO: Sage Therapeutics

ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults. The mechanism of action of brexanolone in treating PPD in adults is related to its positive allosteric modulation of GABAA receptors. Brexanolone potentiated GABA-mediated currents from recombinant human GABAA receptors in mammalian cells expressing 122 receptor subunits, 43 receptor subunits, and 63 receptor subunits.

Postpartum Depression Emerging Therapies

* Ganaxolone: Marinus Pharmaceuticals

Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited anti-epileptic (antiseizure), anxiolytic (anti-anxiety) and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (IV, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patients in acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits antiseizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. Ganaxolone has been designed with an added methyl group that prevents back conversion to an active steroid, which unlocks ganaxolone's potential for chronic use. In preclinical studies, ganaxolone exhibited potency and efficacy comparable to allopregnanolone.

Unlock insights into the Postpartum Depression Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Postpartum Depression Market Forecast. Click here @ Postpartum Depression Market Drivers and Barriers [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Postpartum Depression Market Outlook

Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life.

Scope of the Postpartum Depression Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Postpartum Depression Companies- Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
* Postpartum Depression Pipeline Therapies- SAGE-217/BIIB-125, Ganaxolone, LPCN 1154, BRII-296, and others.
* Postpartum Depression Market Dynamics: Postpartum Depression Market Drivers and Barriers
* Postpartum Depression Market Access and Reimbursement, and Unmet Needs

Gain a strategic edge in the Postpartum Depression Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Postpartum Depression Market Forecast. Click here to lead in advancements @ Postpartum Depression Clinical Trials Assessment [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Postpartum Depression Market Overview at a Glance

4. Executive Summary of Postpartum depression (PPD)

5. Key events

6. Disease Background and Overview

7. Treatment and Management

8. Methodology

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Therapies

12. Emerging Therapies

13. Postpartum Depression (PPD): Seven Major Market Analysis

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=postpartum-depression-therapeutics-market-size-in-the-7mm-was-usd-260-million-in-2023-is-expected-to-grow-by-2034-and-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.